ASCO 2022:幽门螺杆菌感染与胰腺癌之间呈正相关

2022-06-01 MedSci原创 MedSci原创

该研究显示,与胰腺癌相关风险因素,包括年龄、种族、吸烟史、肥胖、饮酒、慢性胰腺炎和糖尿病,幽门螺杆菌感染与胰腺癌呈正相关。

近年来,胰腺癌的发病率在国内外均呈明显的上升趋势。2021年统计数据显示,在美国所有恶性肿瘤中,胰腺癌新发病例男性位列第10位,女性第9位,占恶性肿瘤相关死亡率的第4位。中国国家癌症中心2021年统计数据显示,胰腺癌位居我国男性恶性肿瘤发病率的第7位,女性第11位,占恶性肿瘤相关死亡率的第6位。

众所周知,胰腺癌是一种预后极差的恶性肿瘤,5年总生存率约为9%,而幽门螺杆菌是胃癌和胃黏膜损害的已知危险因素。另外,还有研究显示,幽门螺杆菌感染也会引发十二指肠溃疡、胃肠息肉、结直肠癌,导致便秘、腹泻和体重减轻。目前,幽门螺杆菌是否是胰腺腺癌的危险因素仍不清楚。

以往,研究人员试图通过观察性回顾研究,使用血清学作为幽门螺杆菌感染的标记,以确定幽门螺杆菌与胰腺癌之间是否存在关联,但这些研究的结果不一致。

近期,在ASCO大会上,研究人员通过病例对照,利用食管胃十二指肠镜(EGD)检测幽门螺杆菌组织学来探究幽门螺杆菌感染和胰腺癌的关联。研究人员,分析了 1988 年~ 2018 年田纳西州孟菲斯退伍军人事务医疗中心诊断为胰腺癌患者的数据库,以获得合适的病例。通过对病理学进行检查和病历审查以确定患者是否进行了EGD,以及所做的活检是否进行了幽门螺杆菌检测,同时,幽门螺杆菌的阳性是通过对活检样本进行斯坦纳染色来确定的。在审查了402份病历后,共有51个病例符合上述标准。通过审查所有被检测出幽门螺杆菌的脱氧核糖核酸的病历来获得对照(n=130)。采用单因素和多因素logistic回归分析分析危险因素。

研究结果,与对照组相比,病例组 (53%) 中发现感染幽门螺杆菌的受试者明显更多。使用多元逻辑回归分析显示,与胰腺癌相关风险因素,包括年龄、种族、吸烟史、肥胖、饮酒、慢性胰腺炎和糖尿病。结果显示,胰腺癌患者与有胰腺癌家族史患者和幽门螺杆菌感染显著相关。总之,幽门螺杆菌感染与胰腺癌呈正相关。

参考资料

Steve Otieno, Amit L Jain, Omar Mohammed, Jay R Patel, John Collyer, Peter Deleeuw, Arshad Husain, Alva Bowen Weir.Positive association between Helicobacter pylori infection and pancreatic cancer: A case-control study.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1939387, encodeId=e808193938eaf, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jan 12 11:19:59 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994530, encodeId=ea2a199453030, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Feb 07 18:19:59 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811880, encodeId=d25c18118809f, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Dec 06 14:19:59 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348758, encodeId=3b051348e5873, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 03 06:19:59 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223874, encodeId=bd3212238e4f0, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 01 15:47:06 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2023-01-12 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1939387, encodeId=e808193938eaf, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jan 12 11:19:59 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994530, encodeId=ea2a199453030, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Feb 07 18:19:59 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811880, encodeId=d25c18118809f, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Dec 06 14:19:59 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348758, encodeId=3b051348e5873, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 03 06:19:59 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223874, encodeId=bd3212238e4f0, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 01 15:47:06 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2023-02-07 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1939387, encodeId=e808193938eaf, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jan 12 11:19:59 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994530, encodeId=ea2a199453030, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Feb 07 18:19:59 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811880, encodeId=d25c18118809f, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Dec 06 14:19:59 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348758, encodeId=3b051348e5873, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 03 06:19:59 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223874, encodeId=bd3212238e4f0, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 01 15:47:06 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-12-06 kcb069
  4. [GetPortalCommentsPageByObjectIdResponse(id=1939387, encodeId=e808193938eaf, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jan 12 11:19:59 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994530, encodeId=ea2a199453030, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Feb 07 18:19:59 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811880, encodeId=d25c18118809f, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Dec 06 14:19:59 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348758, encodeId=3b051348e5873, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 03 06:19:59 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223874, encodeId=bd3212238e4f0, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 01 15:47:06 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1939387, encodeId=e808193938eaf, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jan 12 11:19:59 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994530, encodeId=ea2a199453030, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Feb 07 18:19:59 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811880, encodeId=d25c18118809f, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Dec 06 14:19:59 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348758, encodeId=3b051348e5873, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 03 06:19:59 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223874, encodeId=bd3212238e4f0, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Jun 01 15:47:06 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-06-01 ms5000000518166734

    学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习

    0

相关资讯

ASCO 2021: 放射肿瘤学变革下一个浪潮:放射药物追踪并杀死癌细胞

放射肿瘤学变革,医生报告称,接受了一种直接向肿瘤细胞提供辐射的实验性药物的晚期前列腺癌男性的生存率有所提高。

ASCO 2021:皮肤癌免疫疗法新进展

Nivolumab联合Ipilimumab治疗转移性黑色素瘤的延长随访。

ASCO 2021开幕,大流行背景下癌症治疗公平性受关注

大流行背景下癌症治疗公平性受关注

ASCO 2022:结直肠癌发病年轻化,可能与肠道微生物有关!

世界卫生组织癌症研究机构(IRAC)发布的2020年最新癌症数据显示,结直肠癌是仅次于乳腺癌及肺癌的第三大常见癌症,患者占比高达9.4%。其中,中国结直肠癌患者站占全球结直肠癌患者的31%。不仅如此,

ASCO 2022:心脏代谢和腹部脂肪对女性乳腺癌患者身体功能的影响

AAT可能与化疗前的身体功能有更紧密的联系,而在乳腺癌患者治疗期间,心脏代谢特征可能有临床影响。

ASCO速递:第一波剧透来了 ——非小细胞转移性专场

记得阅读梅斯ASCO大会相关报道哦~